Medifast (NYSE:MED) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations

What happened

Medifast reported Q3 2026 revenue of $72.05 million, beating analysts' $71.3 million estimate but falling 19.4% year on year. Its GAAP loss of $1.57 per share badly missed the -$0.35 consensus, while fourth-quarter revenue guidance of $65 million at the midpoint slightly exceeded expectations.

Confirmed

Global impact / market context

Revenue beat expectations, but the far larger per-share loss shows costs are out of line with sales. The 19.4% yearly revenue decline means the business is shrinking, so investors must weigh whether cost cuts and new product launches can restore profit before cash reserves thin.

Analyst inference

Medifast is a small company with a market value of about $122.7 million. Its operating margin fell to -26.9% from -4.6% a year earlier, meaning it now loses money on each sale. Optimistic fourth-quarter guidance is therefore a forecast, not yet a proven turnaround.

Analyst inference

What to watch

1. Watch whether fourth-quarter revenue reaches the guided $65 million midpoint and whether GAAP earnings per share meet the guided $0.13 midpoint, since both figures are company forecasts rather than reported results. Confirmed
2. Watch the operating margin for improvement from -26.9%, which means losses per sale. A narrower loss would signal the Catalyst cost program, a plan to cut expenses, is working as management describes. Analyst inference
3. Watch whether the new compensation plan keeps coaches, the independent sellers of Medifast products. Coach departures would reduce revenue and could undercut the expected returns from the completed brand and product launches. Analyst inference

Evidence

• stockstory.org